Pioglitazone, a Specific Ligand of the Peroxisome Proliferator-Activated Receptor Gamma Reduces Gastric Mucosal Injury Induced by Ischaemia/Reperfusion in Rat

By Konturek P. C.   Brzozowski T.   Kania J.   Kukharsky V.   Bazela K.   Kwiecien S.   Harsch I.   Konturek S. J.   Hahn E. G.  

Scandinavian Journal of Gastroenterology, Vol. 38, Iss. 5, 2003-01 ,pp. : 468-476

Informa Healthcare

Access to resources Recommend Favorite

Is estradiol cardioprotection a nitric oxide-mediated effect?

By Duncan A.C.  

Human Reproduction, Vol. 17, Iss. 7, 2002-07 ,pp. : 1918-1924

Oxford University Press

Access to resources Recommend Favorite

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

By Sidhu J.S.   Cowan D.   Kaski J.-C.  

Journal of the American College of Cardiology, Vol. 42, Iss. 10, 2003-11 ,pp. : 1757-1763

Elsevier

Access to resources Recommend Favorite

Targeting Peroxisome Proliferator-Activated Receptor Gamma for Generation of Antidiabetic Drug

By  

Current Diabetes Reviews, Vol. 9, Iss. 4, 2013-07 ,pp. : 275-285

Bentham Science Publishers

Access to resources Recommend Favorite

A Ligand for Peroxisome Proliferator-Activated Receptor γ Inhibits Human Cholangiocarcinoma Cell Growth: Potential Molecular Targeting Strategy for Cholangioma

By Kobuke T.   Tazuma S.   Hyogo H.   Chayama K.  

Digestive Diseases and Sciences, Vol. 51, Iss. 9, 2006-09 ,pp. : 1650-1657

Springer Publishing Company

Access to resources Recommend Favorite